TriangleNCT00869206 · OUTCOME
Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- from baseline up to 2 years
What was measured
To compare the suppression of serum markers of bone resorption of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing. The number of patients with high \& low CTX values by arm will be reported here.
Analysis population: 266 breast cancer patients who were treated and included in this portion of the substudy.
Groups in this outcome
Breast Cancer 4 Weeks
Patients with Breast Cancer receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
Breast Cancer 12 Weeks
Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Breast Cancer 4 Weeks | 137 |
| Breast Cancer 12 Weeks | 129 |
Reported measurements
Low CTX (<0.415ng/ml)
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Breast Cancer 4 Weeks | 83 | Not reported | Not reported | Not reported | Not reported |
| Breast Cancer 12 Weeks | 75 | Not reported | Not reported | Not reported | Not reported |
High CTX (>0.415ng/ml)
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Breast Cancer 4 Weeks | 54 | Not reported | Not reported | Not reported | Not reported |
| Breast Cancer 12 Weeks | 54 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 83
- group Id
- OG001
- value
- 75
- title
- Low CTX (<0.415ng/ml)
- categories
- measurements
- group Id
- OG000
- value
- 54
- group Id
- OG001
- value
- 54
- title
- High CTX (>0.415ng/ml)
- denoms
- counts
- group Id
- OG000
- value
- 137
- group Id
- OG001
- value
- 129
- units
- Participants
- description
- To compare the suppression of serum markers of bone resorption of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing. The number of patients with high \& low CTX values by arm will be reported here.
- groups
- description
- Patients with Breast Cancer receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Breast Cancer 4 Weeks
- description
- Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- Breast Cancer 12 Weeks
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- 266 breast cancer patients who were treated and included in this portion of the substudy.
- reporting Status
- POSTED
- time Frame
- from baseline up to 2 years
- title
- Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer)
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice